Friday, 8 August 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 08 August 2025
News

Star AbbVie drug impresses... again

 Posted 8 August 2025 AM

AbbVie’s JAK inhibitor Rinvoq has produced some outstanding results in a phase 3 trial evaluating it for the treatment of alopecia.

A 15mg dose, of Rinvoq helped 44.6 per cent of of adult and adolescent patients with severe alopecia areata (AA) achieve 80 per cent or more scalp hair coverage after 24 weeks in study 2 of the phase 3 UP-AA trial, AbbVie reported. 

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.